Business
Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study
A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specia
About this update from Achieve Life Sciences, Inc.
[{"type":"image","alt":"Achieve Life Sciences","displaySize":"","headline":null,"caption":"Achieve Life Sciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":269,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/f01e07053436b73353dd8f78efeb68ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Nz0ojNZV.4IpZgjbhcgTOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f01e07053436b73353dd8f78efeb68ec","width":269,"height":300}},"lazy":false},{"type":"text","content":"A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts ","length":233,"tagName":"p"},{"type":"text","content":"Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use","length":126,"tagName":"p"},{"type":"text","content":"SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new data showing that 6 and 12 weeks of cytisinicline delivers meaningful quitting success, regardless of participants' prior use of smoking cessation medications or number of previous quit attempts.","length":497,"tagName":"p"},{"type":"text","content":"Achieve also announces late-breaking survey data from ORCA-OL, demonstrating participant experience with extended cytisinicline use. These findings will be presented during the Society for Research on Nicotine & Tobacco (SRNT) 2026 Annual Meeting, March 4-7 in Baltimore, Maryland.","length":285,"tagName":"p"},{"type":"text","content":"An oral presentation will examine cytisinicline's efficacy and safety profile according to participants' prior treatment history and number of quit attempts. The analysis pools data from the ORCA-2 and ORCA-3 Phase 3 trials and examines outcomes in 1,602 participants with varying histories of prior quit medications, including varenicline, bupropion, and nicotine replacement therapy (NRT), as well as participants according to whether they had made four o...